首页 > 最新文献

Therapeutic Advances in Cardiovascular Disease最新文献

英文 中文
Sex-related differences in heart failure patients: physiological mechanisms of cardiovascular ageing and evidence-based sex-specific medical therapies. 心力衰竭患者的性别差异:心血管老化的生理机制和基于证据的性别特异性医学治疗
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1177/17539447241309673
Andra Maria Ciutac, Tiberiu Pana, Dana Dawson, Phyo Kyaw Myint

This review aims to describe the sex differences in heart failure (HF) patients, with a particular emphasis on the effect of cardiovascular ageing. Additionally, it takes into consideration the sex-related variation in cardiovascular health and physiology and the role ageing plays in HF and its implications in drug therapy. The pharmacokinetics and pharmacodynamics of the common HF medications, classified according to the established sub-types, are summarised with respect to sex-specific documented findings. Despite numerous studies confirming significant differences in HF outcomes according to sex, there are no current guidelines that consider patients' sex in medical therapy of HF. Moreover, females are significantly under-represented in research trials, as well as under-treated in clinical practice, which hinders our understanding of HF in this demographic. Most of the current knowledge on sex-specific HF therapies is driven by secondary analyses of studies not primarily undertaking sex-specific analyses. Therefore, we propose a multi-faceted approach, including increased awareness among healthcare providers and more inclusive research to create a personalised care plan accounting for sex differences in HF management. Given the highlighted knowledge gaps, it is paramount for new research efforts to account for the different sex phenotypes in HF.

本综述旨在描述心力衰竭(HF)患者的性别差异,特别强调心血管老化的影响。此外,它还考虑了心血管健康和生理的性别相关差异、衰老在心衰中的作用及其对药物治疗的影响。常见心衰药物的药代动力学和药效学,根据已建立的亚型分类,总结了关于性别特异性的文献发现。尽管大量的研究证实了心衰结局在性别上的显著差异,但目前还没有在心衰药物治疗中考虑患者性别的指南。此外,女性在研究试验中的代表性明显不足,在临床实践中治疗不足,这阻碍了我们对这一人群中心衰的理解。目前关于性别特异性心衰治疗的大多数知识都是由非主要进行性别特异性分析的研究的二次分析驱动的。因此,我们建议采用多方面的方法,包括提高医疗保健提供者的认识,以及进行更具包容性的研究,以制定考虑心衰管理性别差异的个性化护理计划。鉴于突出的知识差距,对HF的不同性别表型进行新的研究是至关重要的。
{"title":"Sex-related differences in heart failure patients: physiological mechanisms of cardiovascular ageing and evidence-based sex-specific medical therapies.","authors":"Andra Maria Ciutac, Tiberiu Pana, Dana Dawson, Phyo Kyaw Myint","doi":"10.1177/17539447241309673","DOIUrl":"10.1177/17539447241309673","url":null,"abstract":"<p><p>This review aims to describe the sex differences in heart failure (HF) patients, with a particular emphasis on the effect of cardiovascular ageing. Additionally, it takes into consideration the sex-related variation in cardiovascular health and physiology and the role ageing plays in HF and its implications in drug therapy. The pharmacokinetics and pharmacodynamics of the common HF medications, classified according to the established sub-types, are summarised with respect to sex-specific documented findings. Despite numerous studies confirming significant differences in HF outcomes according to sex, there are no current guidelines that consider patients' sex in medical therapy of HF. Moreover, females are significantly under-represented in research trials, as well as under-treated in clinical practice, which hinders our understanding of HF in this demographic. Most of the current knowledge on sex-specific HF therapies is driven by secondary analyses of studies not primarily undertaking sex-specific analyses. Therefore, we propose a multi-faceted approach, including increased awareness among healthcare providers and more inclusive research to create a personalised care plan accounting for sex differences in HF management. Given the highlighted knowledge gaps, it is paramount for new research efforts to account for the different sex phenotypes in HF.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"19 ","pages":"17539447241309673"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142923213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thanks to reviewers.
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1177/17539447251316497
{"title":"Thanks to reviewers.","authors":"","doi":"10.1177/17539447251316497","DOIUrl":"https://doi.org/10.1177/17539447251316497","url":null,"abstract":"","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"19 ","pages":"17539447251316497"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes among patients with coronary artery bypass grafts presenting with acute coronary syndrome: impact of revascularization. 冠状动脉搭桥术患者出现急性冠状动脉综合征的结果:血运重建的影响。
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1177/17539447241308047
Hilary J Bews, Brett Hiebert, Shuangbo Liu, John Ducas, Amir Ravandi, Kunal Minhas, Malek Kass, Michael P Love, Harindra C Wijeysundera, Ashish H Shah

Background: Patients post-coronary artery bypass graft (CABG) can re-present with acute coronary syndrome (ACS); however, culprit lesion identification, as well as revascularization, is often challenging. Furthermore, the impact of revascularization in this patient group is relatively unknown.

Objectives: The purpose of our study was to evaluate the efficacy of percutaneous coronary intervention (PCI) in patients with previous CABG surgery presenting with ACS.

Methods: Using data from the Manitoba Center for Health Policy, we identified patients treated with CABG between April 1979 and March 2018, who subsequently presented with the primary diagnosis of ACS. Patients were divided into four groups: (1) managed medically and not investigated by cardiac catheterization and (2) investigated by cardiac catheterization and treated (2a) medically, (2b) with PCI, and (2c) with redo-CABG. Inverse probability treatment-weighted survival analyses were performed. Ethical approval was obtained from the local research board.

Results: Nearly 20% of patients treated with CABG presented with ACS at a median of 7.2 years (age at the time of CABG: 66 years (interquartile range: 58-73 years); 75.6% male). Patients treated with PCI (N = 929) demonstrated improved survival compared to the patients investigated by catheterization but treated medically (N = 952; hazard ratio 0.87, 95% confidence interval 0.77-0.97, p = 0.02). Patients who underwent redo CABG (N = 171) experienced 13% mortality within the first year, but subsequently, demonstrated a trend toward improved survival.

Conclusion: ACS is not uncommon following CABG. Revascularization is associated with prognostic improvement; however, such could be accounted for by inherent group differences, including comorbidities and coronary anatomy These findings should be validated in a prospective randomized study.

背景:冠状动脉旁路移植术(CABG)后患者可再次出现急性冠脉综合征(ACS);然而,罪魁祸首病变的识别,以及血运重建,往往是具有挑战性的。此外,在这组患者中,血运重建的影响是相对未知的。目的:本研究的目的是评估经皮冠状动脉介入治疗(PCI)对既往冠脉搭桥患者ACS的疗效。方法:使用马尼托巴卫生政策中心的数据,我们确定了1979年4月至2018年3月期间接受冠脉搭桥治疗的患者,这些患者随后被初步诊断为ACS。患者分为四组:(1)医学治疗,不接受心导管检查;(2)心导管检查,接受治疗(2a)医学治疗,(2b) PCI治疗,(2c) redocabg治疗。进行反概率治疗加权生存分析。获得了当地研究委员会的伦理批准。结果:近20%接受CABG治疗的患者在中位7.2岁时出现ACS (CABG时年龄:66岁(四分位数范围:58-73岁);75.6%的男性)。接受PCI治疗的患者(N = 929)比接受导管治疗但接受药物治疗的患者(N = 952;风险比0.87,95%置信区间0.77 ~ 0.97,p = 0.02)。再次行CABG的患者(N = 171)在第一年的死亡率为13%,但随后表现出改善生存的趋势。结论:冠脉搭桥术后ACS并不少见。血运重建与预后改善有关;然而,这可以通过固有的组差异来解释,包括合并症和冠状动脉解剖。这些发现应该在前瞻性随机研究中得到验证。
{"title":"Outcomes among patients with coronary artery bypass grafts presenting with acute coronary syndrome: impact of revascularization.","authors":"Hilary J Bews, Brett Hiebert, Shuangbo Liu, John Ducas, Amir Ravandi, Kunal Minhas, Malek Kass, Michael P Love, Harindra C Wijeysundera, Ashish H Shah","doi":"10.1177/17539447241308047","DOIUrl":"10.1177/17539447241308047","url":null,"abstract":"<p><strong>Background: </strong>Patients post-coronary artery bypass graft (CABG) can re-present with acute coronary syndrome (ACS); however, culprit lesion identification, as well as revascularization, is often challenging. Furthermore, the impact of revascularization in this patient group is relatively unknown.</p><p><strong>Objectives: </strong>The purpose of our study was to evaluate the efficacy of percutaneous coronary intervention (PCI) in patients with previous CABG surgery presenting with ACS.</p><p><strong>Methods: </strong>Using data from the Manitoba Center for Health Policy, we identified patients treated with CABG between April 1979 and March 2018, who subsequently presented with the primary diagnosis of ACS. Patients were divided into four groups: (1) managed medically and not investigated by cardiac catheterization and (2) investigated by cardiac catheterization and treated (2a) medically, (2b) with PCI, and (2c) with redo-CABG. Inverse probability treatment-weighted survival analyses were performed. Ethical approval was obtained from the local research board.</p><p><strong>Results: </strong>Nearly 20% of patients treated with CABG presented with ACS at a median of 7.2 years (age at the time of CABG: 66 years (interquartile range: 58-73 years); 75.6% male). Patients treated with PCI (<i>N</i> = 929) demonstrated improved survival compared to the patients investigated by catheterization but treated medically (<i>N</i> = 952; hazard ratio 0.87, 95% confidence interval 0.77-0.97, <i>p</i> = 0.02). Patients who underwent redo CABG (<i>N</i> = 171) experienced 13% mortality within the first year, but subsequently, demonstrated a trend toward improved survival.</p><p><strong>Conclusion: </strong>ACS is not uncommon following CABG. Revascularization is associated with prognostic improvement; however, such could be accounted for by inherent group differences, including comorbidities and coronary anatomy These findings should be validated in a prospective randomized study.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"19 ","pages":"17539447241308047"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ascending aortic replacement versus aortic root replacement in patients with type A aortic dissection involving the aortic root. 累及主动脉根部的A型主动脉夹层患者的升主动脉置换术与主动脉根置换术比较。
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1177/17539447241303408
Fausto Biancari, Giuseppe Gatti, Timo Mäkikallio, Tatu Juvonen, Giovanni Mariscalco, Zein El-Dean, Matteo Pettinari, Javier Rodriguez Lega, Andrea Perrotti, Francesco Onorati, Konrad Wisniewki, Till Demal, Petr Kacer, Dario Di Perna, Igor Vendramin, Mauro Rinaldi, Luisa Ferrante, Eduard Quintana, Joscha Buech, Caroline Radner, Antonio Fiore, Angelo M Dell'Aquila, Paola D'Errigo, Stefano Rosato, Gianluca Polvani, Sven Peterss

Background: Extensive surgical resection of the thoracic aorta in patients with type A aortic dissection (TAAD) is thought to reduce the risk of late aortic wall degeneration and the need for repeat aortic operations.

Objectives: We evaluated the early and late outcomes after aortic root replacement and supracoronary ascending aortic replacement in patients with TAAD involving the aortic root.

Design: Retrospective, multicenter cohort study.

Methods: The outcomes after aortic root replacement and supracoronary ascending aortic replacement in patients with TAAD involving the aortic root, that is dissection flap located at least in one of the Valsava segments, were herein evaluated. In-hospital mortality, neurological complications, dialysis as well as 10-year repeat proximal aortic operation, and mortality were the outcomes of this study.

Results: Supracoronary ascending aortic replacement was performed in 198 patients and aortic root replacement in 215 patients. During a mean follow-up of 4.0 ± 4.0 years, 19 patients underwent 22 repeat procedures on the aortic root and/or aortic valve. No operative death occurred after these reinterventions. The risk of proximal aortic reoperation was significantly lower in patients who underwent aortic root replacement (5.5% vs 12.9%, adjusted subdistributional hazard ratio (SHR) 0.085, 95% CI 0.022-0.329). Aortic root replacement was associated with higher rates of in-hospital (14.4% vs 12.1%, adjusted odds ratio 2.192, 95% CI 1.000-4.807) and 10-year mortality (44.5% vs 30.4%, adjusted hazard ratio 2.216, 95% CI 1.338-3.671). Postoperative neurological complications and dialysis rates were comparable in the study groups.

Conclusion: Among patients with TAAD involving the aortic root, its replacement was associated with a significantly lower rate of repeat proximal aortic operation of any type compared to supracoronary aortic replacement. Still, aortic root replacement seems to be associated with an increased risk of mortality in these patients.

ClinicalTrials.gov: NCT04831073 (https://clinicaltrials.gov/study/NCT04831073).

背景:广泛手术切除A型主动脉夹层(TAAD)患者的胸主动脉被认为可以降低晚期主动脉壁退变的风险和重复主动脉手术的需要。目的:我们评估累及主动脉根部的TAAD患者主动脉根部置换术和冠状上升主动脉置换术的早期和晚期预后。设计:回顾性、多中心队列研究。方法:对累及主动脉根部的TAAD患者进行主动脉根部置换术和冠状上升主动脉置换术后的结果进行评价,主动脉根部是指位于至少一个Valsava节段的夹层皮瓣。住院死亡率、神经系统并发症、透析以及10年重复主动脉近端手术和死亡率是本研究的结果。结果:冠状上升主动脉置换术198例,主动脉根置换术215例。在平均4.0±4.0年的随访期间,19例患者接受了22次主动脉根部和/或主动脉瓣重复手术。再干预后无手术死亡。行主动脉根置换术的患者主动脉近端再手术的风险显著降低(5.5% vs 12.9%,调整亚分布风险比(SHR) 0.085, 95% CI 0.022-0.329)。主动脉根部置换术与较高的住院率(14.4% vs 12.1%,校正优势比2.192,95% CI 1.000-4.807)和10年死亡率(44.5% vs 30.4%,校正危险比2.216,95% CI 1.338-3.671)相关。术后神经系统并发症和透析率在各研究组间具有可比性。结论:在累及主动脉根部的TAAD患者中,与冠状动脉上动脉置换术相比,其置换术与任何类型的主动脉近端重复手术的发生率均显著降低。尽管如此,主动脉根部置换术似乎与这些患者死亡风险的增加有关。
{"title":"Ascending aortic replacement versus aortic root replacement in patients with type A aortic dissection involving the aortic root.","authors":"Fausto Biancari, Giuseppe Gatti, Timo Mäkikallio, Tatu Juvonen, Giovanni Mariscalco, Zein El-Dean, Matteo Pettinari, Javier Rodriguez Lega, Andrea Perrotti, Francesco Onorati, Konrad Wisniewki, Till Demal, Petr Kacer, Dario Di Perna, Igor Vendramin, Mauro Rinaldi, Luisa Ferrante, Eduard Quintana, Joscha Buech, Caroline Radner, Antonio Fiore, Angelo M Dell'Aquila, Paola D'Errigo, Stefano Rosato, Gianluca Polvani, Sven Peterss","doi":"10.1177/17539447241303408","DOIUrl":"10.1177/17539447241303408","url":null,"abstract":"<p><strong>Background: </strong>Extensive surgical resection of the thoracic aorta in patients with type A aortic dissection (TAAD) is thought to reduce the risk of late aortic wall degeneration and the need for repeat aortic operations.</p><p><strong>Objectives: </strong>We evaluated the early and late outcomes after aortic root replacement and supracoronary ascending aortic replacement in patients with TAAD involving the aortic root.</p><p><strong>Design: </strong>Retrospective, multicenter cohort study.</p><p><strong>Methods: </strong>The outcomes after aortic root replacement and supracoronary ascending aortic replacement in patients with TAAD involving the aortic root, that is dissection flap located at least in one of the Valsava segments, were herein evaluated. In-hospital mortality, neurological complications, dialysis as well as 10-year repeat proximal aortic operation, and mortality were the outcomes of this study.</p><p><strong>Results: </strong>Supracoronary ascending aortic replacement was performed in 198 patients and aortic root replacement in 215 patients. During a mean follow-up of 4.0 ± 4.0 years, 19 patients underwent 22 repeat procedures on the aortic root and/or aortic valve. No operative death occurred after these reinterventions. The risk of proximal aortic reoperation was significantly lower in patients who underwent aortic root replacement (5.5% vs 12.9%, adjusted subdistributional hazard ratio (SHR) 0.085, 95% CI 0.022-0.329). Aortic root replacement was associated with higher rates of in-hospital (14.4% vs 12.1%, adjusted odds ratio 2.192, 95% CI 1.000-4.807) and 10-year mortality (44.5% vs 30.4%, adjusted hazard ratio 2.216, 95% CI 1.338-3.671). Postoperative neurological complications and dialysis rates were comparable in the study groups.</p><p><strong>Conclusion: </strong>Among patients with TAAD involving the aortic root, its replacement was associated with a significantly lower rate of repeat proximal aortic operation of any type compared to supracoronary aortic replacement. Still, aortic root replacement seems to be associated with an increased risk of mortality in these patients.</p><p><p>ClinicalTrials.gov: NCT04831073 (https://clinicaltrials.gov/study/NCT04831073).</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"19 ","pages":"17539447241303408"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11752557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carotid artery atherosclerosis, low and high volumes of high-intensity interval training in patients after myocardial infarction: the precision of measurement embarks on a precise measurement protocol.
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1177/17539447251318932
Christian Saleh
{"title":"Carotid artery atherosclerosis, low and high volumes of high-intensity interval training in patients after myocardial infarction: the precision of measurement embarks on a precise measurement protocol.","authors":"Christian Saleh","doi":"10.1177/17539447251318932","DOIUrl":"10.1177/17539447251318932","url":null,"abstract":"","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"19 ","pages":"17539447251318932"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thanks to Reviewers. 感谢审稿人。
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-01 DOI: 10.1177/17539447251316497
{"title":"Thanks to Reviewers.","authors":"","doi":"10.1177/17539447251316497","DOIUrl":"10.1177/17539447251316497","url":null,"abstract":"","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"19 ","pages":"17539447251316497"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous image-guided management of a misplaced pericardiocentesis catheter into the inferior vena cava. 经皮图像引导处理误入下腔静脉的心包穿刺导管。
IF 2.3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.1177/17539447241234655
Haytham Derbel, Mahdi Krichen, Youssef Zaarour, Salim Jazzar, Mario Ghosn, Vania Tacher, Hicham Kobeiter

Misplacement of pericardiocentesis catheter in central veins is a rare complication that can be managed with several methods. In this case, we report a percutaneous image-guided plug-assisted management of a misplaced pericardiocentesis catheter into the inferior vena cava through a transhepatic tract successfully occluded. This minimally invasive technique was not previously described in this setting and had a favorable long-term outcome.

心包穿刺导管误入中心静脉是一种罕见的并发症,可通过多种方法进行处理。在本病例中,我们报告了一种经皮图像引导下的插管辅助治疗方法,成功堵塞了一条经肝导管进入下腔静脉的错位心包穿刺导管。这种微创技术以前从未在这种情况下使用过,而且长期疗效良好。
{"title":"Percutaneous image-guided management of a misplaced pericardiocentesis catheter into the inferior vena cava.","authors":"Haytham Derbel, Mahdi Krichen, Youssef Zaarour, Salim Jazzar, Mario Ghosn, Vania Tacher, Hicham Kobeiter","doi":"10.1177/17539447241234655","DOIUrl":"10.1177/17539447241234655","url":null,"abstract":"<p><p>Misplacement of pericardiocentesis catheter in central veins is a rare complication that can be managed with several methods. In this case, we report a percutaneous image-guided plug-assisted management of a misplaced pericardiocentesis catheter into the inferior vena cava through a transhepatic tract successfully occluded. This minimally invasive technique was not previously described in this setting and had a favorable long-term outcome.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"18 ","pages":"17539447241234655"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10894529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139940846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coronary intravascular lithotripsy in contemporary practice: challenges and opportunities in coronary intervention. 当代实践中的冠状动脉血管内碎石术:冠状动脉介入治疗的挑战与机遇。
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.1177/17539447241263444
Ankush Gupta, Abhinav Shrivastava, Jaskaran Singh Dugal, Sanya Chhikara, Rajesh Vijayvergiya, Navreet Singh, Ajit Chandrakant Mehta, Nalin Kumar Mahesh, Ajay Swamy

Percutaneous coronary intervention (PCI) of calcified coronary arteries is associated with poor outcomes. Poorly modified calcified lesion hinders the stent delivery, disrupts drug-carrying polymer, impairs drug elution kinetics and results in under-expanded stent (UES). UES is the most common cause of acute stent thrombosis and in-stent restenosis after PCI of calcified lesions. Angiography has poor sensitivity for recognition and quantification of coronary calcium, thereby mandating the use of intravascular imaging. Intravascular imaging, like intravascular ultrasound and optical coherence tomography, has the potential to accurately identify and quantify the coronary calcium and to guide appropriate modification device before stent placement. Available options for the modification of calcified plaque include modified balloons (cutting balloon, scoring balloon and high-pressure balloon), atherectomy devices (rotational atherectomy and orbital atherectomy) and laser atherectomy. Coronary intravascular lithotripsy (IVL) is the newest addition to the tool box for calcified plaque modification. It produces the acoustic shockwaves, which interact with the coronary calcium to cause multiplanar fractures. These calcium fractures increase the vessel compliance and result in desirable minimum stent areas. Coronary IVL has established its safety and efficacy for calcified lesion in series of Disrupt CAD trials. Its advantages over atherectomy devices include ease of use on workhorse wire, ability to modify deep calcium, no debris embolization causing slow flow or no-flow and minimal thermal injury. It is showing promising results in modification of difficult calcified lesion subsets such as calcified nodule, calcified left main bifurcation lesions and chronic total occlusion. In this review, authors will summarize the mechanism of action for IVL, its role in contemporary practice, evidence available for its use, its advantages over atherectomy devices and its imaging insight in different calcified lesion scenarios.

钙化冠状动脉的经皮冠状动脉介入治疗(PCI)效果不佳。钙化病变修饰不良会阻碍支架输送、破坏载药聚合物、影响药物洗脱动力学并导致支架扩张不足(UES)。UES是钙化病变PCI术后急性支架血栓形成和支架内再狭窄的最常见原因。血管造影在识别和量化冠状动脉钙化方面的灵敏度较低,因此必须使用血管内成像。血管内成像,如血管内超声和光学相干断层扫描,可以准确识别和量化冠状动脉钙化,并在支架置入前指导适当的改造装置。可用于改造钙化斑块的方法包括改造球囊(切割球囊、刻痕球囊和高压球囊)、粥样体切除装置(旋转式粥样体切除术和轨道式粥样体切除术)和激光粥样体切除术。冠状动脉血管内碎石术(IVL)是钙化斑块改造工具箱中的最新成员。它产生的声波冲击波与冠状动脉钙质相互作用,造成多平面断裂。这些钙质断裂增加了血管的顺应性,使支架面积达到理想的最小值。冠状动脉 IVL 在一系列 Disrupt CAD 试验中证实了其对钙化病变的安全性和有效性。与动脉粥样硬化切除装置相比,它的优点包括:易于在工作母线上使用、能够改变深层钙化、无碎片栓塞导致血流缓慢或无血流以及热损伤最小。它在改造钙化结节、钙化左主干分叉病变和慢性全闭塞等疑难钙化病变亚群方面显示出良好的效果。在这篇综述中,作者将总结 IVL 的作用机制、它在当代实践中的作用、使用 IVL 的证据、它与动脉粥样硬化切除设备相比的优势,以及它在不同钙化病变情况下的成像效果。
{"title":"Coronary intravascular lithotripsy in contemporary practice: challenges and opportunities in coronary intervention.","authors":"Ankush Gupta, Abhinav Shrivastava, Jaskaran Singh Dugal, Sanya Chhikara, Rajesh Vijayvergiya, Navreet Singh, Ajit Chandrakant Mehta, Nalin Kumar Mahesh, Ajay Swamy","doi":"10.1177/17539447241263444","DOIUrl":"10.1177/17539447241263444","url":null,"abstract":"<p><p>Percutaneous coronary intervention (PCI) of calcified coronary arteries is associated with poor outcomes. Poorly modified calcified lesion hinders the stent delivery, disrupts drug-carrying polymer, impairs drug elution kinetics and results in under-expanded stent (UES). UES is the most common cause of acute stent thrombosis and in-stent restenosis after PCI of calcified lesions. Angiography has poor sensitivity for recognition and quantification of coronary calcium, thereby mandating the use of intravascular imaging. Intravascular imaging, like intravascular ultrasound and optical coherence tomography, has the potential to accurately identify and quantify the coronary calcium and to guide appropriate modification device before stent placement. Available options for the modification of calcified plaque include modified balloons (cutting balloon, scoring balloon and high-pressure balloon), atherectomy devices (rotational atherectomy and orbital atherectomy) and laser atherectomy. Coronary intravascular lithotripsy (IVL) is the newest addition to the tool box for calcified plaque modification. It produces the acoustic shockwaves, which interact with the coronary calcium to cause multiplanar fractures. These calcium fractures increase the vessel compliance and result in desirable minimum stent areas. Coronary IVL has established its safety and efficacy for calcified lesion in series of Disrupt CAD trials. Its advantages over atherectomy devices include ease of use on workhorse wire, ability to modify deep calcium, no debris embolization causing slow flow or no-flow and minimal thermal injury. It is showing promising results in modification of difficult calcified lesion subsets such as calcified nodule, calcified left main bifurcation lesions and chronic total occlusion. In this review, authors will summarize the mechanism of action for IVL, its role in contemporary practice, evidence available for its use, its advantages over atherectomy devices and its imaging insight in different calcified lesion scenarios.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"18 ","pages":"17539447241263444"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11273719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing coronary artery plaque analysis via artificial intelligence-driven cardiovascular computed tomography. 通过人工智能驱动的心血管计算机断层扫描增强冠状动脉斑块分析。
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.1177/17539447241303399
Jeffrey Xia, Kinan Bachour, Abdul-Rahman M Suleiman, Jacob S Roberts, Sammy Sayed, Geoffrey W Cho

Coronary computed tomography angiography (CCTA) is a noninvasive imaging modality of cardiac structures and vasculature considered comparable to invasive coronary angiography for the evaluation of coronary artery disease (CAD) in several major cardiovascular guidelines. Conventional image acquisition, processing, and analysis of CCTA imaging have progressed significantly in the past decade through advances in technology, computation, and engineering. However, the advent of artificial intelligence (AI)-driven analysis of CCTA further drives past the limitations of conventional CCTA, allowing for greater achievements in speed, consistency, accuracy, and safety. AI-driven CCTA (AI-CCTA) has achieved a significant reduction in radiation exposure for patients, allowing for high-quality scans with sub-millisievert radiation doses. AI-CCTA has demonstrated comparable accuracy and consistency in manual coronary artery calcium scoring against expert human readers. An advantage over invasive coronary angiography, which provides luminal information only, CCTA allows for plaque characterization, providing detailed information on the quality of plaque and offering further prognosticative value for the management of CAD. Combined with AI, many recent studies demonstrate the efficacy, accuracy, efficiency, and precision of AI-driven analysis of CCTA imaging for the evaluation of CAD, including assessing degree stenosis, adverse plaque characteristics, and CT fractional flow reserve. The limitations of AI-CCTA include its early phase in investigation, the need for further improvements in AI modeling, possible medicolegal implications, and the need for further large-scale validation studies. Despite these limitations, AI-CCTA represents an important opportunity for improving cardiovascular care in an increasingly advanced and data-driven world of modern medicine.

在一些主要的心血管指南中,冠状动脉计算机断层血管造影(CCTA)是一种无创的心脏结构和血管成像方式,被认为可与有创冠状动脉造影相媲美,用于评估冠状动脉疾病(CAD)。传统的图像采集、处理和CCTA成像分析在过去十年中通过技术、计算和工程的进步取得了重大进展。然而,人工智能(AI)驱动的CCTA分析的出现进一步突破了传统CCTA的局限性,在速度、一致性、准确性和安全性方面取得了更大的成就。人工智能驱动的CCTA (AI-CCTA)显著减少了患者的辐射暴露,允许以亚毫西弗辐射剂量进行高质量扫描。AI-CCTA在人工冠状动脉钙评分方面与人类专家读者表现出相当的准确性和一致性。与仅提供腔内信息的侵入性冠状动脉造影相比,CCTA的优势在于允许斑块表征,提供斑块质量的详细信息,并为CAD的管理提供进一步的预测价值。结合人工智能,最近的许多研究证明了人工智能驱动的CCTA成像分析对CAD评估的有效性、准确性、效率和精确性,包括评估狭窄程度、不良斑块特征和CT分数血流储备。AI- ccta的局限性包括其调查的早期阶段,需要进一步改进AI建模,可能的医学意义,以及需要进一步的大规模验证研究。尽管存在这些限制,AI-CCTA代表了在日益先进和数据驱动的现代医学世界中改善心血管护理的重要机会。
{"title":"Enhancing coronary artery plaque analysis via artificial intelligence-driven cardiovascular computed tomography.","authors":"Jeffrey Xia, Kinan Bachour, Abdul-Rahman M Suleiman, Jacob S Roberts, Sammy Sayed, Geoffrey W Cho","doi":"10.1177/17539447241303399","DOIUrl":"10.1177/17539447241303399","url":null,"abstract":"<p><p>Coronary computed tomography angiography (CCTA) is a noninvasive imaging modality of cardiac structures and vasculature considered comparable to invasive coronary angiography for the evaluation of coronary artery disease (CAD) in several major cardiovascular guidelines. Conventional image acquisition, processing, and analysis of CCTA imaging have progressed significantly in the past decade through advances in technology, computation, and engineering. However, the advent of artificial intelligence (AI)-driven analysis of CCTA further drives past the limitations of conventional CCTA, allowing for greater achievements in speed, consistency, accuracy, and safety. AI-driven CCTA (AI-CCTA) has achieved a significant reduction in radiation exposure for patients, allowing for high-quality scans with sub-millisievert radiation doses. AI-CCTA has demonstrated comparable accuracy and consistency in manual coronary artery calcium scoring against expert human readers. An advantage over invasive coronary angiography, which provides luminal information only, CCTA allows for plaque characterization, providing detailed information on the quality of plaque and offering further prognosticative value for the management of CAD. Combined with AI, many recent studies demonstrate the efficacy, accuracy, efficiency, and precision of AI-driven analysis of CCTA imaging for the evaluation of CAD, including assessing degree stenosis, adverse plaque characteristics, and CT fractional flow reserve. The limitations of AI-CCTA include its early phase in investigation, the need for further improvements in AI modeling, possible medicolegal implications, and the need for further large-scale validation studies. Despite these limitations, AI-CCTA represents an important opportunity for improving cardiovascular care in an increasingly advanced and data-driven world of modern medicine.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"18 ","pages":"17539447241303399"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diversity in the editorial boards of medical journals: a perspective from the Middle East. 医学期刊编辑委员会的多样性:来自中东的视角。
IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-01-01 DOI: 10.1177/17539447241300022
Zainab Atiyah Dakhil, Mohammed Dheyaa Marsool Marsool, Mohammed Saad Qasim, May Saad Al-Jorani

Despite the significant increase in women in academic medicine over the last 50 years, women are still under-represented in leadership positions in academia. However, there is a lack of data on the diversity of editorial boards in Middle Eastern medical journals. So, we aim to portray the diversity of editorial boards of Iraqi medical journals by conducting a cross-sectional analysis of the editorial boards' members of all Iraqi medical journals. Gender, affiliation and specialty were extracted from the journals' websites and/or from the professional profiles of the editorial board members. Twenty-five journals and 446 editorial board members were analysed. More than half of editorial board members specialized in basic science, while 39.76% specialized in clinical specialties. Approximately, 20.18% of editorial board members (regardless their role) were women. Four percent of editor-in-chief were women. There were significant differences in editorial role according to gender (p < 0.0001), yet residency (p = 0.688) and specialty (p = 0.190) did not differ according to their gender. Most editorial board members were affiliated with Baghdad. So, we can conclude that there is a significant under-representation of women across all roles on the editorial board of medical journals especially in the leading positions. All stakeholders, publishers, authors and academics should commit to ensure the diversity of editorial boards.

尽管在过去 50 年里,学术医学界的女性人数大幅增加,但女性在学术界领导岗位上的人数仍然不足。然而,有关中东医学期刊编辑委员会多样性的数据却很缺乏。因此,我们旨在通过对所有伊拉克医学期刊编委会成员进行横向分析,描绘伊拉克医学期刊编委会的多样性。性别、所属单位和专业均从期刊网站和/或编委会成员的专业简介中提取。对 25 种期刊和 446 名编委会成员进行了分析。半数以上的编委会成员专攻基础科学,39.76%专攻临床专业。约 20.18% 的编委会成员(无论其角色如何)为女性。4%的主编为女性。编辑角色在性别上有明显差异(P = 0.688),而专业(P = 0.190)在性别上没有差异。大多数编辑委员会成员隶属于巴格达。因此,我们可以得出结论,在医学期刊编委会的所有职位中,女性的比例严重不足,尤其 是在领导岗位上。所有利益相关方、出版商、作者和学者都应致力于确保编委会的多样性。
{"title":"Diversity in the editorial boards of medical journals: a perspective from the Middle East.","authors":"Zainab Atiyah Dakhil, Mohammed Dheyaa Marsool Marsool, Mohammed Saad Qasim, May Saad Al-Jorani","doi":"10.1177/17539447241300022","DOIUrl":"10.1177/17539447241300022","url":null,"abstract":"<p><p>Despite the significant increase in women in academic medicine over the last 50 years, women are still under-represented in leadership positions in academia. However, there is a lack of data on the diversity of editorial boards in Middle Eastern medical journals. So, we aim to portray the diversity of editorial boards of Iraqi medical journals by conducting a cross-sectional analysis of the editorial boards' members of all Iraqi medical journals. Gender, affiliation and specialty were extracted from the journals' websites and/or from the professional profiles of the editorial board members. Twenty-five journals and 446 editorial board members were analysed. More than half of editorial board members specialized in basic science, while 39.76% specialized in clinical specialties. Approximately, 20.18% of editorial board members (regardless their role) were women. Four percent of editor-in-chief were women. There were significant differences in editorial role according to gender (<i>p</i> < 0.0001), yet residency (<i>p</i> = 0.688) and specialty (<i>p</i> = 0.190) did not differ according to their gender. Most editorial board members were affiliated with Baghdad. So, we can conclude that there is a significant under-representation of women across all roles on the editorial board of medical journals especially in the leading positions. All stakeholders, publishers, authors and academics should commit to ensure the diversity of editorial boards.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"18 ","pages":"17539447241300022"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Therapeutic Advances in Cardiovascular Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1